Inha University Hospital

Running trials

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

• Recruiting

  AI-Based Cardiac Analysis Using 12-Lead and 1-Lead ECG

  NCT07844434· Inha University Hospital· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Autologous Adipose-Derived Stem Cell Injections for Knee Osteoarthritis

  NCT07901790· Yonsei University· Source

• Recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

  NCT07589595· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

  NCT07533006· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Clinical Efficacy of Implementing an AI-SaMD for Funduscopy Analysis in Patients With Diabetes Mellitus

  NCT07378956· VUNO Inc.· Source

• Recruiting

  Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines

  NCT07415551· Phase 2· Yuhan Corporation· Source

• Not yet recruiting

  Dronedarone Rhythm Intervention for Early Atrial Fibrillation

  NCT07270848· Phase 4· Inha University Hospital· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Taiho Oncology, Inc.· Source

• Recruiting

  ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

  NCT07007559· Phase 2· ALX Oncology Inc.· Source

• Recruiting

  A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Neuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease

  NCT07239310· Deepsonbio· Source

• Recruiting

  AI-Based Prediction of Atrial Fibrillation in ESUS Patients With ICM

  NCT07347691· Inha University Hospital· Source

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of Brenipatide in Participants With Alcohol Use Disorder

  NCT07219953· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

  NCT07011745· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

  NCT06757764· Phase 4· Asan Medical Center· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2

  NCT06742931· Samsung Medical Center· Source

• Recruiting

  Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)

  NCT06889818· Ewha Womans University Mokdong Hospital· Source

• Recruiting

  ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

  NCT05672836· Phase 4· Duk-Woo Park, MD· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Eli Lilly and Company· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke

  NCT06649240· Seoul National University Hospital· Source

• Recruiting

  Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

  NCT06603558· AbbVie· Source

• Recruiting

  Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

  NCT06184009· Phase 2· Jae Wook Lee· Source

• Active, not recruiting

  A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

  NCT06161441· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Fractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease

  NCT05829889· Seung-Jung Park· Source

• Enrolling by invitation

  ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

  NCT06194799· Phase 3· ACADIA Pharmaceuticals Inc.· Source

• Active, not recruiting

  Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE

  NCT05995600· Phase 4· Seoul National University Hospital· Source

• Active, not recruiting

  A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

  NCT06256328· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Active, not recruiting

  REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

  NCT05973773· Phase 3· Taiho Oncology, Inc.· Source

• Recruiting

  AI-Based Differential Diagnosis and Localization of Tachycardia Using ECG: Multicenter Registry (EP-AI ASSIST)

  NCT07859020· Inha University Hospital· Source

• Recruiting

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· Phase 2/3· ACADIA Pharmaceuticals Inc.· Source

• Active, not recruiting

  Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation

  NCT06027307· Phase 3· Asan Medical Center· Source

• Recruiting

  A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

  NCT06012240· Phase 3· AbbVie· Source

• Recruiting

  A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

  NCT06016842· Phase 3· Ipsen· Source

• Active, not recruiting

  A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

  NCT05800015· Phase 2/3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

  NCT05967689· Phase 2· Taiho Oncology, Inc.· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  AI-Powered Electrocardiography for Diagnosis and Prognostic Prediction in Cardiovascular Disease (AI-CVD): Multicenter Retrospective Study

  NCT07856472· Inha University Hospital· Source

Showing 50 of 64.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease8 recruiting
• Heart failure5 recruiting
• Atrial fibrillation4 recruiting
• Mild cognitive impairment4 recruiting
• Coronary artery disease3 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Lung cancer3 recruiting
• Obesity3 recruiting
• Stroke3 recruiting
• Alopecia areata2 recruiting
• Metastatic breast cancer2 recruiting
• Type 2 diabetes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Aortic stenosis1 recruiting
• Childhood cancers1 recruiting
• Chronic spontaneous urticaria1 recruiting
• Diabetic eye disease1 recruiting
• High blood pressure1 recruiting
• Lewy body dementia1 recruiting
• Liver cirrhosis1 recruiting
• Migraine1 recruiting
• Osteoarthritis1 recruiting
• Pancreatic cancer1 recruiting
• Parkinson disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Sarcoma1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  Cognitive Therapy Software for Improving Cognitive Function for Patients With Mild Cognitive Impairment

  NCT06264557· Rowan· Source

• Terminated

  A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

  NCT06113328· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

  NCT05646862· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients

  NCT05815901· Phase 3· JW Pharmaceutical· Source

• Completed

  Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH

  NCT06297434· Phase 2· J2H Biotech· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Amgen· Source

• Completed

  Da-vinci sp Versus xi Thyroid Surgery

  NCT06573268· Inha University Hospital· Source

• Completed

  Phase 2 Study of DKN-01 in Colorectal Cancer

  NCT05480306· Phase 2· Leap Therapeutics, Inc.· Source

• Completed

  Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

  NCT05153239· Phase 3· PharmaMar· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

  NCT04846881· Phase 3· Boehringer Ingelheim· Source

• Completed

  Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

  NCT04952779· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis

  NCT04541810· AbbVie· Source

• Completed

  Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

  NCT04433442· AbbVie· Source

• Completed

  Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and Hypercholesterolemia

  NCT06293261· Yuhan Corporation· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients

  NCT03776123· Ipsen· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Daiichi Sankyo· Source

• Completed

  Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

  NCT03377491· Phase 3· NovoCure Ltd.· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source

• Completed

  Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea

  NCT03288974· Celgene· Source

• Completed

  Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer

  NCT03310632· Phase 1/2· Golden Biotechnology Corporation· Source

• Completed

  Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

  NCT03025308· Phase 3· Alfasigma S.p.A.· Source

• Completed

  XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice

  NCT02042300· Seung-Jung Park· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Myasthenia gravis7 works · 0 trials